Gummy Vitamin recall: FDA Flags B12 supplements sold on Amazon, Aldi — See which brands are affected

Details of the Recalled Products
Welby (sold at Aldi): 1,000 mcg B12, 140-count bottle; UPC: 4099100290868
Berkley Jensen (sold at BJ's Wholesale Club): 1,000 mcg B12, 250-count bottle; UPC: 888670132487
VitaGlobe (sold online, including Amazon): Extra Strength B12, 60-count bottle; UPC: 850005214670
No Reports of Illness Yet, Recall Issued as Precaution
Live Events
Routine Testing Triggered the Recall
What Consumers Should Do
FAQs
Why were the B12 gummy vitamins recalled?
Have there been any reported health incidents linked to the gummy vitamin recall?
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
A batch of gummy vitamins sold across major U.S. retailers including Amazon, Aldi, and BJ's Wholesale Club has been voluntarily recalled following the detection of a potentially dangerous undeclared allergen. The move was announced by Vita Warehouse Corp. on June 12, following standard allergen testing procedures initiated by one of the retailers.The recall applies to specific lots of B12 gummy vitamins marketed under the brand names Welby , Berkley Jensen, and VitaGlobe . The U.S. Food and Drug Administration (FDA) confirmed in a public advisory that the recalled products may contain traces of peanuts, posing a risk to individuals with allergies or severe sensitivity.The affected Gummy Vitamins, as mentioned in a report by USA Today, have been identified as follows:All three products belong to the Lot Number 248046601 and carry an expiration date of October 2026. The packaging consists of clear bottles with white caps and variations in label colors. The lot number and expiry date are printed on the bottom of the bottles.According to the FDA, there have been no confirmed illnesses or allergic reactions linked to the consumption of the affected vitamin gummies. Nonetheless, the recall was issued 'out of an abundance of caution,' especially in light of the potentially severe consequences for peanut-allergic consumers.Peanut allergies can lead to life-threatening reactions, including anaphylaxis. The FDA has urged consumers with known sensitivities to immediately discontinue use of the identified products.The allergen was flagged during routine label-verification testing by Aldi. Although Vita Warehouse Corp.'s own testing did not detect peanut residue, the single adverse result was enough to initiate a recall. The FDA stated that the retailer's protocol included verification of a 'does not contain peanuts' claim, which one product reportedly failed.Importantly, the agency has clarified that no other products under the Welby, Berkley Jensen, or VitaGlobe brand names are impacted by this recall.Customers in possession of the recalled products—particularly those with peanut allergies—are advised to return the items to their point of purchase for a full refund or dispose of them safely. The FDA has emphasized that anyone experiencing symptoms of an allergic reaction should seek immediate medical care.Consumers with questions can reach Vita Warehouse Corp. via their toll-free helpline at 1-855-214-0100 (Monday through Friday, 7:30 a.m. to 4:00 p.m. EST).The recall was issued after routine testing detected the presence of an undeclared allergen—peanut residue—in one of the products. While no illnesses have been reported, the recall was initiated as a precaution to protect consumers with peanut allergies.No, the U.S. Food and Drug Administration (FDA) confirmed there have been no illnesses or allergic reactions reported so far. The recall was issued as a preventive measure.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Time of India

16 hours ago

• Time of India

Dose of hope

Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.

Hans India

a day ago

• Hans India

ZeroHarm Eyes Rs 150 Crore Milestone by FY 2025 -'26, Accelerates Global Expansion into GCC

ZeroHarm Sciences, India's pioneering clean-label nutraceutical company, is set to accelerate its global footprint with a focused expansion into the GCC markets, including the UAE and the broader Middle East. Following a remarkable 10× revenue growth over the past two years and operating at a healthy ~20% EBITDA margin, the company closed the last fiscal year with 71 crore in gross revenue with an exit ARR of 90 crores. In the current fiscal, ZeroHarm is aiming for ₹150 crore in gross revenue, driven by strong domestic and global momentum and increasing traction in the United States, which now contributes nearly 30% of its overall revenue. At the heart of ZeroHarm's global success is its patented ZeroHarm BioEnhance platform, a pharma-grade nanotechnology that encapsulates plant-based actives at the nanoscale, dramatically enhancing their bioavailability by up to 5×, ensuring faster onset, precise dosing, and residue-free delivery. This breakthrough, backed by granted patents and deep R&D, makes ZeroHarm the first Indian company to bring pharmaceutical nanotech into nutraceuticals at scale. ZeroHarm's US FDA, CE, and ISO-certified formulations are backed by government-led clinical trials, with documented claims for 15 products, setting it apart in a market rife with unverified health claims. Today, the company offers over 70 targeted, condition-specific products spanning diabetes, arthritis, PCOS, liver and kidney health, immunity, and oncology support, with over million units sold across India to date. Backed by a fully owned, nanotech-enabled manufacturing facility, ZeroHarm can produce up to ₹250 crore worth of finished goods annually, making it one of the few Indian nutraceutical brands with true end-to-end production capabilities. To support its international expansion, ZeroHarm has acquired a dedicated manufacturing and R&D facility in the United States, enhancing local supply chain efficiency, fast-tracking formulation innovation, and enabling closer clinical and regulatory collaborations in key global markets. The U.S. infrastructure also gives ZeroHarm a significant strategic edge in developed markets, where stringent compliance standards often limit entry for Indian nutraceutical brands reliant on contract manufacturing. 'The global nutraceutical market is shifting, consumers are demanding not just clean labels, but clinical credibility. At ZeroHarm, we've combined deep R&D with pharma-grade nanotechnology to raise the bar for efficacy, safety, and transparency in preventive wellness. Our entry into the GCC is a natural extension of the trust we've built in India and the U.S., and a significant step toward making evidence-backed, plant-based therapeutics accessible to global consumers,' said Sachin Darbarwar, Founder & CEO, ZeroHarm Sciences. With distribution agreements and regulatory filings already underway, the company will also launch in the UK aside from the GCC markets by Q3 2025, introducing its clinically tested product lines via pharmacies, e-commerce platforms, and integrative practitioner networks.

Indian Express

a day ago

• Indian Express

Scientists say they may have found a way to extend human lifespan

For decades, scientists have been trying to find a way to extend human lifespan, and while studies have shown that select lab animals can live longer by eating less, they haven't conducted these studies on humans. A century-old study on lab rats has shown that mice who eat less often outlive their fed counterparts, but it can be almost impossible for most humans to follow a permanent diet. However, a new study by the School of Biological Sciences, University of East Anglia, claims that a combination of FDA-approved drugs that mimic the effects of dieting might be the answer to a longer life. The two drugs – Rapamycin and Metformin are known to extend the lifespan of mice as much as up to 30 per cent. Rapamycin, which was first found in the 1970s in bacteria living on the Easter Island soil, has been traditionally used as a powerful immunosuppressant to prevent organ-transplant rejection. The drug works by disabling a particular switch which is used to inform cells when a cell has an abundance of nutrients. As for Metformin, it is a synthetic compound that is found in French Lilac or Goat's Rue, which doctors prescribe to control sugar levels in type 2 diabetes. Since both of these drugs are used to sense the nutrient and energy levels in the human body, biologists wanted to see if the combination of these drugs could have the same effect as eating less. To know more about their effects, scientists say they examined thousands of existing studies and came across 167 studies that focused on eight vertebrate species, like fish and monkeys, which offered them a detailed insight into how these drugs affected animals. Out of three strategies that help with longevity, eating less, taking Rapamycin and consuming Metformin, scientists say the most dependable way to increase the lifespan is to eat less, irrespective of the animal's sex. They also noted that the second most effective strategy to increase lifespan was to take Rapamycin, while Metformin had no substantial effect. However, scientists did say that the effect of Rapamycin on animals wasn't consistent, as, in some cases, studies have shown that eating less or taking Rapamycin reduced an animal's lifespan. Another thing to note here is that most of these positive effects were on mice and rats, which have genes similar to humans but are not exactly the same. And since Rapamycin does come with some side effects, like reduced immunity, scientists are now trying to see if lower doses of the drug offer some advantages without the side effects. According to an ongoing Rapamycin trial on humans, it was noted that lower doses of the drug might help increase the lifespan. But, as of now, the trial is still in progress and will take a few years before the results are out.